The role of cold ischemia time and hypothermic perfusion in predicting early hepatocellular carcinoma recurrences after liver transplantation

Abstract

AbstractAimThe aim of the study was to identify predictors of early tumor recurrence in patients with hepatocellular carcinoma (HCC) after liver transplantation (LT).MethodsRetrospective cohort study in 237 consecutive liver recipients with HCC between 2016 and 2021. Multivariate logistic analysis was performed to identify predictors of early HCC recurrences. The impact of hypothermic‐oxygenated perfusion (HOPE) on outcome was analyzed after propensity score weighting.ResultsEarly recurrences were observed in 15 cases. Microvascular invasion (OR 3.737, 95% CI 1.246–11.206, p = 0.019) and cold ischemia time (OR 1.155, 95% CI 1.001–1.333, p = 0.049) were independently associated with a lower risk of HCC recurrences. After balancing for relevant variables, patients in the HOPE group had lower rates of tumor recurrence (weighted OR 0.126, 95% CI 0.016–0.989, p = 0.049) and higher recurrence free survival (weighted HR 0.132, 95% CI 0.017–0.999, p = 0.050).ConclusionReducing cold ischemia time and graft perfusion with HOPE can lead to lower rates of early HCC recurrences and higher recurrence‐free survival.